US 12,258,399 B2
Methods for achieving therapeutically effective doses of anti-CD47 agents
Stephen Willingham, Sunnyvale, CA (US); Maureen Howard, Los Altos Hills, CA (US); Jie Liu, Palo Alto, CA (US); Ravindra Majeti, Palo Alto, CA (US); Susan Sweeney Prohaska, Mountain View, CA (US); Anne Kathrin Volkmer, Duesseldorf (DE); Jens-Peter Volkmer, Menlo Park, CA (US); and Irving L. Weissman, Stanford, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed on Aug. 12, 2021, as Appl. No. 17/401,046.
Application 16/375,238 is a division of application No. 15/423,325, filed on Feb. 2, 2017, granted, now 10,301,387, issued on May 28, 2019.
Application 17/401,046 is a continuation of application No. 17/102,183, filed on Nov. 23, 2020, granted, now 11,136,391.
Application 17/102,183 is a continuation of application No. 16/375,238, filed on Apr. 4, 2019, granted, now 11,104,731, issued on Aug. 31, 2021.
Application 15/423,325 is a continuation of application No. 14/769,069, granted, now 9,623,079, issued on Apr. 18, 2017, previously published as PCT/US2014/018743, filed on Feb. 26, 2014.
Claims priority of provisional application 61/800,102, filed on Mar. 15, 2013.
Prior Publication US 2021/0380689 A1, Dec. 9, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 38/17 (2006.01); C07K 16/28 (2006.01); A61K 38/18 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 38/1774 (2013.01); A61K 39/3955 (2013.01); C07K 16/2896 (2013.01); A61K 38/1816 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01); Y02A 50/30 (2018.01)] 18 Claims
OG exemplary drawing
 
1. A method for treating cancer in a human subject, the method comprising:
(a) administering a sub-therapeutic dose of from 0.1 mg/kg to 10 mg/kg of an anti-CD47 antibody that blocks the interaction between CD47 and SIRPα, wherein the sub-therapeutic dose is sufficient to increase production of reticulocytes; and
(b) administering a therapeutically effective dose of an anti-CD47 antibody that blocks the interaction between CD47 and SIRPα; wherein step (b) is performed in a range of from 5 to 9 days after beginning step (a), thereby treating the cancer.